Zentalis Pharmaceuticals (ZNTL) EBITDA Margin (2024)
Zentalis Pharmaceuticals' quarterly EBITDA Margin came in at 185.55% in Q4 2024, down 203.9% quarter-over-quarter from 61.06% in Q1 2024.
Zentalis Pharmaceuticals has reported EBITDA Margin for 1 years, with the latest figure at 185.55% in Q4 2024.
- For the quarter ending Q4 2024, EBITDA Margin changed N/A year-over-year to 185.55%; the trailing twelve-month figure through Sep 2025 stood at 615.16% (down 9922.0% YoY), and the FY2024 full-year result was 283.57%, changed N/A from the prior year.
- EBITDA Margin for Q4 2024 stood at 185.55%, down from 61.06% in the prior quarter.
- The five-year high for EBITDA Margin was 61.06% in Q1 2024, with the low at 185.55% in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -185.55% |
| Mar 31, 2024 | -61.06% |